What determines biodistribution of a radiopharmaceutical?
The biodistribution of a radiopharmaceutical is determined primarily by the chemical structure of the carrier molecule, as well as physiological factors such as blood flow, membrane transport, receptor expression, metabolism, and excretion pathways.
The radionuclide itself generally does not determine where the tracer accumulates; rather, it is the biological behaviour of the labelled compound that dictates organ uptake. Physical properties such as molecular size, charge, lipophilicity, and protein binding also influence tissue distribution.
Biodistribution is determined by the biological and chemical properties of the radiopharmaceutical, including perfusion, receptor binding, metabolism, and clearance pathways.
Biodistribution ultimately reflects the interaction between tracer chemistry and human physiology.
Understanding the physics
A radiopharmaceutical consists of a radionuclide attached to a biologically active molecule. Once injected, the compound follows physiological pathways governed by its molecular properties.
Several key factors determine where it accumulates. This is a very brief overview:
Blood flow and perfusion influence initial delivery. Highly perfused organs such as the brain, liver, and kidneys receive tracer rapidly.
Cell membrane transport mechanisms affect uptake. For example, FDG enters cells via glucose transporters and becomes trapped after phosphorylation. Without appropriate transport mechanisms, uptake will be limited regardless of perfusion.
Receptor expression or binding sites determine localisation for receptor-targeted tracers. The density and affinity of receptors directly influence tracer accumulation.
Metabolism and biochemical trapping can retain tracers within cells. FDG trapping occurs because FDG-6-phosphate is not further metabolised.
Molecular size and lipophilicity influence distribution across membranes. Lipophilic tracers cross the blood–brain barrier more readily than hydrophilic compounds.
Plasma protein binding alters availability for tissue uptake. Highly protein-bound tracers may have slower tissue distribution.
Excretion pathways affect background activity. Renal or hepatobiliary clearance patterns influence image contrast and timing.
Importantly, the radionuclide contributes physical detectability but does not dictate biological targeting unless it alters the chemistry of the compound.
Where this matters clinically
Understanding biodistribution explains normal uptake patterns and common physiological variants. It also clarifies why image timing is critical as early and delayed images may show very different tracer distribution.
Abnormal biodistribution may reflect altered physiology, disease processes, or radiochemical instability.